Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NAVIDEA BIOPHARMACEUTICALS, INC.

(NAVB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
1.57(c) 1.59(c) 1.56(c) 1.56(c) 1.57(c) Last
58 729 23 050 16 940 24 397 102 541 Volume
-3.68% +1.27% -1.89% 0.00% +0.64% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 9,39 M - -
Net income 2021 -4,82 M - -
Net Debt 2021 - - -
P/E ratio 2021 -9,81x
Yield 2021 -
Sales 2022 3,95 M - -
Net income 2022 -14,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,03x
Yield 2022 -
Capitalization 47,3 M 47,3 M -
Capi. / Sales 2021 5,04x
Capi. / Sales 2022 12,0x
Nbr of Employees 16
Free-Float 72,3%
More Financials
Company
Navidea Biopharmaceuticals, Inc. (Navidea) is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company focuses on two drug product diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694; and therapeutic development programs, including therapeutic... 
More about the company
Ratings of Navidea Biopharmaceuticals, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about NAVIDEA BIOPHARMACEUTICALS, INC.
09/17NAVIDEA BIOPHARMACEUTICALS : Announces Changes to Board of Directors Composition..
PU
09/17NAVIDEA BIOPHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Su..
AQ
09/17NAVIDEA BIOPHARMACEUTICALS' : Board Chair Retires, Replacement Named
MT
09/17NAVIDEA BIOPHARMACEUTICALS : Announces Changes to Board of Directors Composition
BU
09/17Navidea Biopharmaceuticals Announces Board and Committee Changes
CI
08/12NAVIDEA BIOPHARMACEUTICALS : Management's Discussion and Analysis of Financial C..
AQ
08/11NAVIDEA BIOPHARMACEUTICALS : Reports Second Quarter 2021 Financial Results (Form..
PU
08/11NAVIDEA BIOPHARMACEUTICALS, INC. : Results of Operations and Financial Condition..
AQ
08/11Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quar..
CI
08/11NAVIDEA : Q2 Earnings Snapshot
AQ
08/11NAVIDEA BIOPHARMACEUTICALS : Q2 Loss Shrinks Even as Revenue Falls
MT
08/11NAVIDEA BIOPHARMACEUTICALS : Reports Second Quarter 2021 Financial Results
BU
08/04NAVIDEA BIOPHARMACEUTICALS : to Host Second Quarter 2021 Earnings Conference Cal..
BU
07/26NAVIDEA BIOPHARMACEUTICALS : Investor Presentation
PU
07/19NAVIDEA BIOPHARMACEUTICALS : Announces First 110 Subjects Imaged in NAV3-35 Norm..
BU
More news
News in other languages on NAVIDEA BIOPHARMACEUTICALS, INC.

- No features available -

More news
Chart NAVIDEA BIOPHARMACEUTICALS, INC.
Duration : Period :
Navidea Biopharmaceuticals, Inc. Technical Analysis Chart | NAVB | US63937X2027 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,57 $
Average target price 6,50 $
Spread / Average Target 314%
EPS Revisions
Managers and Directors
Jed Andrew Latkin CEO, COO, CFO, Secretary, Treasurer & Director
Amit Bhalla Chairman
Michael S. Rosol Chief Medical Officer
William J. Regan Chief Compliance & Regulatory Officer
Claudine E. Bruck Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NAVIDEA BIOPHARMACEUTICALS, INC.-26.98%47
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420